Taysha Gene Therapies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Taysha Gene Therapies is forecast to grow earnings and revenue by 14% and 51.8% per annum respectively while EPS is expected to grow by 24% per annum.

Wichtige Informationen

14.0%

Wachstumsrate der Gewinne

24.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmen51.8%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Good

Zuletzt aktualisiert30 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20

Taysha: Produces Solid Data But Has Abandoned Programs

Feb 06

Taysha Gene Therapies Gets A 'Thumbs Up'

Mar 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TSHA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202637-83-115-976
12/31/20255-104-66-8011
12/31/20248-89-75-6112
6/30/202413-114-79-75N/A
3/31/202414-118-76-73N/A
12/31/202315-112-80-73N/A
9/30/202314-214-52-42N/A
6/30/202310-124-62-53N/A
3/31/20237-133-85-68N/A
12/31/20223-166-113-88N/A
9/30/2022N/A-161-174-143N/A
6/30/2022N/A-186-179-146N/A
3/31/2022N/A-193-168-136N/A
12/31/2021N/A-175-139-117N/A
9/30/2021N/A-142-116-97N/A
6/30/2021N/A-106-87-71N/A
3/31/2021N/A-87-61-51N/A
12/31/2020N/A-60-40-31N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TSHA is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: TSHA is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: TSHA is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: TSHA's revenue (51.8% per year) is forecast to grow faster than the US market (8.9% per year).

Hohe Wachstumseinnahmen: TSHA's revenue (51.8% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if TSHA's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken